Lieve Brochez

List of Publications by Year
in descending order

95 papers	3,119 citations	126907 33 h-index	168389 53 g-index
100 all docs	100 docs citations	100 times ranked	5457 citing authors

#	Article	IF	Citations
1	The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. European Journal of Cancer, 2017, 76, 167-182.	2.8	234
2	Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death and Differentiation, 2014, 21, 1250-1261.	11.2	195
3	Cancer risk in immune-mediated inflammatory diseases (IMID). Molecular Cancer, 2013, 12, 98.	19.2	104
4	IDO Expression in Cancer: Different Compartment, Different Functionality?. Frontiers in Immunology, 2020, 11, 531491.	4.8	104
5	Chronic and Invasive Fungal Infections in a Family with CARD9 Deficiency. Journal of Clinical Immunology, 2016, 36, 204-209.	3.8	98
6	Characterization of thein vivoimmune network of IDO, tryptophan metabolism, PD-L1, andCTLA-4in circulating immune cells in melanoma. OncoImmunology, 2015, 4, e982382.	4.6	95
7	Acute generalized exanthematous pustulosis: anÂoverview ofÂtheÂclinical, immunological andÂdiagnostic concepts. European Journal of Dermatology, 2010, 20, 425-433.	0.6	93
8	Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. European Journal of Cancer, 2012, 48, 2004-2011.	2.8	92
9	Dysplastic Nevi. New England Journal of Medicine, 2003, 349, 2233-2240.	27.0	90
10	Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. European Urology, 2019, 75, 707-711.	1.9	89
11	EGFR in melanoma: clinical significance and potential therapeutic target. Journal of Cutaneous Pathology, 2011, 38, 492-502.	1.3	77
12	miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells. International Journal of Oncology, 2013, 42, 1443-1451.	3.3	76
13	Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. European Journal of Cancer, 2017, 86, 358-363.	2.8	72
14	Three-dimensional skin models as tools for transdermal drug delivery: challenges and limitations. Expert Opinion on Drug Delivery, 2011, 8, 705-720.	5.0	68
15	Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?. Current Opinion in Oncology, 2019, 31, 54-64.	2.4	66
16	Peritumoral indoleamine 2,3â€dioxygenase expression in melanoma: an early marker of resistance to immune control?. British Journal of Dermatology, 2014, 171, 987-995.	1.5	63
17	New insights in segmental vitiligo: case report and review of theories. British Journal of Dermatology, 2012, 166, 240-246.	1.5	61
18	Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening. British Journal of Dermatology, 2016, 174, 1258-1265.	1.5	56

#	Article	IF	Citations
19	Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. Journal of Translational Medicine, 2015, 13, 9.	4.4	54
20	Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review. Case Reports in Dermatology, 2018, 10, 190-197.	0.8	54
21	Total-Body Examination vs Lesion-Directed Skin Cancer Screening. JAMA Dermatology, 2016, 152, 27.	4.1	51
22	The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype. Cancer Research, 2020, 80, 2983-2995.	0.9	51
23	Charting Extracellular Transcriptomes in The Human Biofluid RNA Atlas. Cell Reports, 2020, 33, 108552.	6.4	50
24	Rosettes and other white shiny structures in polarized dermoscopy: histological correlate and optical explanation. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 311-313.	2.4	47
25	The role of VEGF-C staining in predicting regional metastasis in melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 257-265.	2.8	46
26	A CARD9 Founder Mutation Disrupts NF-Î¹B Signaling by Inhibiting BCL10 and MALT1 Recruitment and Signalosome Formation. Frontiers in Immunology, 2018, 9, 2366.	4.8	46
27	Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma. International Journal of Radiation Oncology Biology Physics, 2019, 104, 828-835.	0.8	46
28	Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. Pigment Cell and Melanoma Research, 2011, 24, 334-344.	3.3	45
29	A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. Cancer Immunology, Immunotherapy, 2020, 69, 2589-2598.	4.2	44
30	Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 741-746.	2.4	39
31	Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports. Endocrine, 2014, 47, 878-883.	2.3	37
32	In vivo vitiligo induction and therapy model: doubleâ€blind, randomized clinical trial. Pigment Cell and Melanoma Research, 2012, 25, 57-65.	3.3	36
33	Long non-coding RNAs in cutaneous melanoma: clinical perspectives. Oncotarget, 2017, 8, 43470-43480.	1.8	35
34	Burden of skin cancer in Belgium and cost-effectiveness of primary prevention by reducing ultraviolet exposure. Preventive Medicine, 2016, 93, 177-182.	3.4	34
35	The distribution pattern of segmental vitiligo: clues for somatic mosaicism. British Journal of Dermatology, 2013, 168, 56-64.	1.5	33
36	The role of RhoC in growth and metastatic capacity of melanoma. Journal of Cutaneous Pathology, 2009, 36, 629-636.	1.3	31

#	Article	IF	Citations
37	Prognostic value and clinical significance of halo naevi regarding vitiligo. British Journal of Dermatology, 2011, 164, 743-749.	1.5	31
38	Different phenotypes of segmental vitiligo based on a clinical observational study. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 673-678.	2.4	31
39	A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma. Neoplasia, 2018, 20, 218-225.	5.3	31
40	A crossâ€sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 507-511.	2.4	30
41	Phase 1 Dose Escalation Trial of Ipilimumab andÂStereotactic Body Radiation Therapy in Metastatic Melanoma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 906-915.	0.8	30
42	A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. Journal of Translational Medicine, 2017, 15, 150.	4.4	26
43	Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma. Nature Communications, 2018, 9, 2921.	12.8	26
44	Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile. Oncotarget, 2018, 9, 25216-25224.	1.8	26
45	Clinical significance of Koebner phenomenon in vitiligo. British Journal of Dermatology, 2012, 167, 1017-1024.	1.5	25
46	Clinical significance of the expression of c-Ski and SnoN, possible mediators in TGF-Î² resistance, in primary cutaneous melanoma. Journal of Dermatological Science, 2009, 53, 26-33.	1.9	23
47	Skin Cancer Detection Using Infrared Thermography: Measurement Setup, Procedure and Equipment. Sensors, 2022, 22, 3327.	3.8	22
48	A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. Journal of Translational Medicine, 2017, 15, 21.	4.4	21
49	Cost-effectiveness and Budget Effect Analysis of a Population-Based Skin Cancer Screening. JAMA Dermatology, 2017, 153, 147.	4.1	21
50	P-cadherin counteracts myosin II-B function: implications in melanoma progression. Molecular Cancer, 2010, 9, 255.	19.2	19
51	Incidence of scabies in Belgium. Epidemiology and Infection, 2008, 136, 395-398.	2.1	18
52	Halo naevi with associated vitiligoâ€like depigmentations: pathogenetic hypothesis. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 755-761.	2.4	18
53	The melanoma burden in Belgium; premature morbidity and mortality make melanoma a considerable health problem. Melanoma Research, 1999, 9, 614-618.	1.2	17
54	A short dermoscopy training increases diagnostic performance in both inexperienced and experienced dermatologists. Australasian Journal of Dermatology, 2015, 56, 52-55.	0.7	17

#	Article	IF	Citations
55	Systemic immune changes associated with adjuvant interferon-Î±2b-therapy in stage III melanoma patients. Melanoma Research, 2015, 25, 357-361.	1.2	13
56	High-Resolution 18F-FDG PET/CT for Assessing Three-Dimensional Intraoperative Margins Status in Malignancies of the Head and Neck, a Proof-of-Concept. Journal of Clinical Medicine, 2021, 10, 3737.	2.4	13
57	The haptoglobin phenotype influences the risk of cutaneous squamous cell carcinoma in kidney transplant patients. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 566-571.	2.4	12
58	Efficacy of Products to Remove Eggs of <I>Pediculus humanus capitis</I> (Phthiraptera: Pediculidae) From the Human Hair. Journal of Medical Entomology, 2014, 51, 400-407.	1.8	12
59	Association of haptoglobin phenotypes with the development of Kaposiâ€™s sarcoma in HIV patients. Archives of Dermatological Research, 2011, 303, 763-769.	1.9	10
60	Comparison of Ex Vivo and In Vivo Dermoscopy in Dermatopathologic Evaluation of Skin Tumors. JAMA Dermatology, 2016, 152, 312.	4.1	10
61	Enhanced visualization of blood and pigment in multispectral skin dermoscopy. Skin Research and Technology, 2020, 26, 708-712.	1.6	10
62	Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial. BMC Cancer, 2021, 21, 514.	2.6	10
63	Pathologic Evaluation of Skin Tumors With Ex Vivo Dermoscopy With Derm Dotting. JAMA Dermatology, 2017, 153, 154.	4.1	9
64	Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNÎ³-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma. Frontiers in Immunology, 2021, 12, 736498.	4.8	8
65	Value of Dermoscopy in a Population-Based Screening Sample by Dermatologists. Dermatology Practical and Conceptual, 2019, 9, 200-206.	0.9	7
66	Recommendations for skin cancer consultation and surgery during COVIDâ€19 pandemic. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1876-1878.	2.4	6
67	Dermatological side effects of current and upcoming targeted therapies in oncology. Acta Clinica Belgica, 2011, 66, 97-103.	1.2	6
68	Lesionâ€directed screening to optimize skin cancer detection in dermatology practice: an observational study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1309-1314.	2.4	5
69	Immune mediated mechanisms of melanocyte destruction. OncoImmunology, 2012, 1, 526-528.	4.6	4
70	Charting Extracellular Transcriptomes in the Human Biofluid RNA Atlas. SSRN Electronic Journal, 0, , .	0.4	4
71	Basal cell carcinoma in older adults: how to decide when active surveillance or watchful waiting is appropriate?. British Journal of Dermatology, 2022, 187, 244-245.	1.5	4
72	Successful Treatment of HCV-associated B-Cell Non-Hodgkin Lymphomas With Direct-acting Antiviral Agents. Journal of Clinical Gastroenterology, 2016, 50, 438.	2.2	3

#	Article	IF	Citations
73	Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures. Cancers, 2021, 13, 2630.	3.7	3
74	Health state utility instruments in patients with keratinocyte cancer and actinic keratosis: a crossâ€sectional study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	3
75	Haptoglobin polymorphism and the risk of actinic keratoses and cutaneous squamous cell carcinoma: A caseâ€“control study. Journal of Dermatology, 2019, 46, 274-275.	1.2	2
76	Hypomelanoses Associated with Melanocytic Neoplasia. , 0, , 705-724.		2
77	Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 789473.	4.8	2
78	OC-0682: Phase 1 trial of pembrolizumab with SBRT in metastatic urothelial carcinoma. Radiotherapy and Oncology, 2018, 127, S357-S358.	0.6	1
79	26915 Steps towards trustworthy AI: Detecting unsupported lesions. Journal of the American Academy of Dermatology, 2021, 85, AB26.	1.2	1
80	Phase II study of ipilimumab (IPI) in children and adolescents with unresectable stage III or IV malignant melanoma (MEL).. Journal of Clinical Oncology, 2017, 35, e21006-e21006.	1.6	1
81	Dynamic Infrared Thermography (DIRT) in Biomedical Applications: DIEP Flap Breast Reconstruction and Skin Cancer. Engineering Proceedings, 2021, 8, 3.	0.4	1
82	P032. Indoleamine 2,3 dioxygenase. Melanoma Research, 2011, 21, e34.	1.2	0
83	P069. The haptoglobin phenotype influences the risk of cutaneous squamous cell carcinoma in kidney transplant patients. Melanoma Research, 2011, 21, e55.	1.2	0
84	Phase I trial of stereotactic body radiotherapy with concurrent fixed dose ipilimumab in metastatic melanoma: Dose limiting toxicity and abscopal effect. Annals of Oncology, 2015, 26, viii5.	1.2	0
85	Systemic treatment influences on immune accessibility of melanoma: A retrospective histopathological investigation. Annals of Oncology, 2016, 27, vi388.	1.2	0
86	Chemoprevention of basal cell carcinoma: reply from authors. British Journal of Dermatology, 2016, , .	1.5	0
87	Chemoprevention of basal cell carcinoma: reply from authors. British Journal of Dermatology, 2016, 175, 1404-1405.	1.5	0
88	OC-0017: Combined High Dose Radiation and Ipilimumab in Metastatic Melanoma, a Phase I Dose Escalation Trial. Radiotherapy and Oncology, 2017, 123, S5.	0.6	0
89	Successful strategy to treat a solitary cystic melanoma brain metastasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e216-e217.	2.4	0
90	Three-dimensional margin assessment in head and neck malignancies using a submillimetric 18F-FDG PET/CT, results of an ongoing clinical trial. Oral Oncology, 2021, 118, 5.	1.5	0

#	Article	IF	Citations
91	Randomized Phase 1 Trial of Pembrolizumab with Neo-Adjuvant Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0
92	Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results.. Journal of Clinical Oncology, 2019, 37, 422-422.	1.6	0
93	Abstract PR15: Charting extracellular transcriptomes in The Human Biofluid RNA Atlas. , 2020, , .		0
94	The value of measuring uncertainty in neural networks in dermoscopy. Journal of the American Academy of Dermatology, 2022, , .	1.2	0
95	Superficial granulomatous pyoderma with ocular involvement. European Journal of Dermatology, 2010, 20, 648-9.	0.6	0